Conditioning regimen of 5-day decitabine administration for allogeneic stem cell transplantation in patients with myelodysplastic syndrome and myeloproliterative neoplasms

Owing to poor prognosis and limited therapeutic modalities, treatment of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) has long been a challenge for researchers [1,2]. In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has provided a potential curative therapy for patients with MDS and MDS/MPN. However, relapse, treatment-related death, and non-relapse mortality (NRM) – which are often related to graft-versus-host disease (GVHD)—remain major obstacles to universally successful transplantation.

Source: Biology of Blood and Marrow Transplantation - September 4, 2019 Category: Hematology Authors: Yi-Geng Cao, Yi He, Su-Dong Zhang, Zi-Xian Liu, Wei-Hua Zhai, Qiao-Ling Ma, Ai-Ming Pang, Jia-Ling Wei, Dong-Ling Yang, Yong Huang, Si-Zhou Feng, Er-Lie Jiang, Ming-Zhe Han Source Type: research